Coating processes – Medical or dental purpose product; parts; subcombinations;...
Reexamination Certificate
2005-07-26
2009-11-24
Barr, Michael (Department: 1792)
Coating processes
Medical or dental purpose product; parts; subcombinations;...
C427S002240, C427S002250, C427S002280, C427S002300, C427S231000, C427S232000, C427S233000, C427S234000, C427S335000, C427S236000, C427S238000, C427S239000, C427S294000, C427S296000, C427S377000, C427S378000, C427S398400, C427S421100, C427S424000, C427S425000, C623S001160, C623S001460, C623S001340, C514S183000, C522S153000
Reexamination Certificate
active
07622145
ABSTRACT:
Processes for coating implantable medical devices that improve the stability of therapeutic agents contained within the coating.
REFERENCES:
patent: 5464650 (1995-11-01), Berg et al.
patent: 6299604 (2001-10-01), Ragheb et al.
patent: 6586048 (2003-07-01), Welch et al.
patent: 6743462 (2004-06-01), Pacetti
patent: 2002/0037944 (2002-03-01), Shen et al.
patent: 2002/0182392 (2002-12-01), Welch et al.
patent: 2003/0083646 (2003-05-01), Sirhan et al.
patent: 2003/0204245 (2003-10-01), Brightbill
patent: 2003/0207856 (2003-11-01), Tremble et al.
patent: 2004/0063805 (2004-04-01), Pacetti et al.
patent: 03/000308 (2003-01-01), None
patent: 03/079936 (2003-10-01), None
Continuous PPV-containing films obtained from parylene develop yellow-green fluorescent colour on exposure to bromine vapour at elevateed temperature, Nov. 20, 1991, Derwent Information LTD.
Anonymous, RD332081A, Dec. 1991, Derwent Information Ltd, abstract only.
Anonymous, Continuos PPV-contg. films obtd. from parylene develop yellow-green fluorescent colour on exposure to bromine vapour at elevated temp., Dec. 10, 1991, Derwent Infformation LTD, (listed as RD332081A).
Campbell et al., “Phenotypic Modulation fo Smooth Muscle Cells in Primary Culture”, no. date provided, Vascular Smooth Muscle in Culture, vol. 1, pp. 39-52.
Berk, B. C. et al., “Heparins and Glucocorticoids Inhibit Restenosis,” J. Am. Coll. Cardiol., 1991, 17, 111B-117B.
Campbell, G. R., et al., “Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis,” Exp. Mol. Pathol., Apr. 1985, 42(2), 139-162.
Chang, M. W. et al., “Adenovirus-mediated Over-expression of the Cyclin/Cyclin-dependent,” J. Clin. Invest., 1995, 96: 2260-2268.
Clowes, A. W. et al., “Kinetics of cellular proliferation after arterial injury. II. Inhibition of smooth muscle growth by heparin,” Lab. Invest., 1985, 52(6), 611-616.
Clowes, A. W. et al., “Kinetics of cellular proliferation after arterial injury. IV. Heparin inhibits rat smooth muscle mitogenesis and migration,” Circ. Res., 1986, 58(6), 839-845.
Clowes, A. W. et al., “Significance of quiescent smooth muscle migration in the injured rat carotid artery,” Circ Res. 1985, 56(1), 139-145.
Clowes, A. W., “Suppression by heparin of smooth muscle cell proliferation in injured arteries,” Nature, 1977, 265(5595), 625-626.
Colburn, M. D. et al., “Dose responsive suppression of myointimal hyperplasia by dexamethasone,” J. Vasc. Surg., 1992, 15, 510-518.
Currier, J. W. et al., “Colchicine Inhibits Restenosis After Iliac Angioplasty in the Atherosclerotic Rabbit,” Circ., 1989, 80(4), 11-66.
Edelman, E. R. et al., “Pathobiologic responses to stenting,” Am J. Cardiol. 1998, 81(7A), 4E-6E.
Farb, A. et al., “Vascular smooth muscle cell cytotoxicity and sustained inhibition of neointimal formation by fibroblast growth factor 2-saporin fusion protein,” Circ. Res., 1997, 80, 542-550.
Ferns, G. A. A. et al., “Inhibition of Neointimal Smooth Muscle Accumulation After Angioplasty by an Antibody to PDGF,” Science, 1991, 253, 1129-1132.
Fischman, D. L. et al., “A Randomized Comparison of Coronary-Stent Placement and Balloon Angioplasty in the Treatment of Coronary Artery Disease,” N. Eng. J. Med., Aug. 25, 1994, 331(8), 496-501.
Franklin, S. M. et al., “Pharmacologic prevention of restenosis after coronary angioplasty: review of the randomized clinical trails,” Coron Artery Dis. Mar. 1993, 4(3), 232-242.
Fukuyama, J. et al., “Tranilast suppresses the vascular intimal hyperplasia after balloon injury in rabbits fed on a high-cholesterol diet,” Eur. J. Pharmacol., 1996, 318, 327-332.
Guyton, J. R. et al., “Inhibition of rat arterial smooth muscle cell proliferation by heparin. In vivo studies with anticoagulant and nonanticoagulant heparin,” Circ. Res., 1980, 46, 625-634.
Hansson, G. K. et al., “Interferon-γ Inhibits Arterial Stenosis After Injury,” Circ., 1991, 84, 1266-1272.
Jonasson, J. et al., “Cyclosporin A inhibits smooth muscle proliferation in the vascular response to injury,” Proc. Natl., Acad. Sci., 1988, 85, 2303-2306.
Lang, R. J. et al., “Effects of 2,3-butanedione monoxime on whole-cell Ca2+ channel currents in single cells of the guinea-pig taenia caeci,” J Physiol. Feb. 1991, 433, 1-24.
Lang, R. J. et al., “Effects of okadaic acid and ATP gamma S on cell length and Ca(2+)-channel currents recorded in single smooth muscle cells of the guinea-pig taenia caeci.,”, Br. J. Pharmacol., Oct. 1991, 104(2), 331-336.
Liu, M. W. et al., “Trapidil in Preventing Restenosis After Balloon Angioplasty in the Atherosclerotic Rabbit,” Circ., 1990, 81, 1089-1093.
Lundergan, C. F. et al., “Terbinafine inhibits the mitogenic response to platelet-derived growth factor in vitro and neointimal proliferation in vivo,” Am. J. Cardiol., 1991, 17(Suppl. B), 132B-136B.
Majesky, M. W. et al., “Heparin regulates smooth muscle S phase entry in the injured rat carotid artery,” Circ. Res., 1987, 61, 296-300.
Mak, K-H. et al., “Clinical trials to prevent restenosis after percutaneous coronary revascularization,” Ann N Y Acad Sci., Apr. 15, 1997, 255-84; discussion 284-8. Review.
Marx, S. O. et al., “Rapamycin-FKBP Inhibits Cell Cycle Regulators of Proliferation in Vascular Smooth Muscle Cells,” Circ. Res., 1995, 76, 412-417.
Nemecek, G. M. et al., “Terbinafine Inhibits the Mitogenic Response to Platelet-Derived Growth Factor in Vitro and Neoinimal Proliferation in Vivo,” J. Pharmacol. Exp. Thera., 1989, 248, 1167-1174.
Okada, T. et al., “Localized Release of Perivascular Heparin Inhibits Intimal Proliferation after Endothelial Injury without Systemic Anticoagulation,” Neurosurgery, 1989, 25, 92-98.
Popma, J. J. et al , “Atherectomy of right coronary ostial stenoses: initial and long-term results, technical features and histologic findings,” Am J Cardiol., Feb. 15, 1991; 67(5), 431-3.
Popma, J. J. et al., “Adjuncts to thrombolysis for myocardial reperfusion,” Ann Intern Med., Jul. 1, 1991, 115(1), 34-44.
Popma, J. J. et al., “Clinical trials of restenosis after coronary angioplasty,” Circulation, Sep. 1991, 84(3), 1426-1436.
Popma, J. J. et al., “Clinical, angiographic and procedural correlates of quantitative coronary dimensions after directional coronary atherectomy,” J Am Coll Cardiol., Nov. 1, 1991, 18(5), 1183-1189.
Powell, J. S. et al., “Inhibitors of Angiotensin-Converting Enzyme Prevent Myointimal Proliferation After Vascular Injury,” Science, 1989, 245, 186-188.
Serruys, P. W. et al., “A comparison of balloon-expandable-stent implantation with balloon angioplasty in patients with coronary artery disease,” N Engl J Med, Aug. 25, 1994; 331(8), 489-495.
Serruys, P. W. et al., “Evaluation of ketanserin in the prevention of restenosis after percutaneous transluminal coronary angioplasty. A multicenter randomized double-blind placebo-controlled trial,” Circulation. Oct. 1993; 88(4 Pt 1), 1588-1601.
Serruys, P. W. et al., “Heparin-coated Palmaz-Schatz stents in human coronary arteries. Early outcome of the Benestent-II Pilot Study,” Circulation, Feb. 1, 1996; 93(3), 412-422.
Serruys, P. W. et al., “Restenosis revisited: insights provided by Quantitative coronary angiography,” Am Heart J, Nov. 1993; 126(5), 1243-1267.
Serruys, P. W. et al., “The bailout stent. Is a friend in need always a friend indeed?” Circulation, Nov. 1993; 88(5 Pt 1), 2455-2457.
Surruys, P. W. et al., “Randomized Trials of Coronary Stenting,”Journal of Interventional Cardiology, 1994, 7(4), 331.
Simons, M. et al., “Antisense c-myboligonucleotides inhibit intimal arterial smooth muscle cell accum
Akerman Eugena A.
Cleeren Dirk
Llanos Gerard
Maryanoff Cynthia A.
Papandreou Georgios
Barr Michael
Bowman Andrew
Cordis Corporation
Evens Carl J.
LandOfFree
Method of coating stents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of coating stents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of coating stents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4096062